Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 30.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Goldbrunner, Roland; Minniti, G; Preusser, M; Jenkinson, M D; Sallabanda, K; Houdart, E; von Deimling, A; Stavrinou, P; Lefranc, F; Lund-Johansen, M; Moyal, E C; Brandsma, D; Henriksson, R; Soffietti, R; Weller, M (2016). EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncology, 17(9):e383-e391.

Weller, Michael; Weber, Ruthild G; Willscher, Edith; Riehmer, Vera; Hentschel, Bettina; Kreuz, Markus; Felsberg, Jörg; Beyer, Ulrike; Löffler-Wirth, Henry; Kaulich, Kerstin; Steinbach, Joachim P; Hartmann, Christian; Gramatzki, D; Schramm, J; Westphal, M; Schackert, G; Simon, M; Martens, T; Boström, J; Hagel, C; Sabel, M; Krex, D; Tonn, J C; Wick, W; Noell, S; Schlegel, U; Radlwimmer, B; Pietsch, T; Loeffler, M; von Deimling, A; Binder, H; Reifenberger, G (2015). Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 129(5):679-693.

Reuss, D E; Sahm, F; Schrimpf, D; Wiestler, B; Capper, D; Koelsche, C; Schweizer, L; Korshunov, A; Jones, D T W; Hovestadt, V; Mittelbronn, M; Schittenhelm, J; Herold-Mende, C; Unterberg, A; Platten, M; Weller, M; Wick, W; Pfister, S M; von Deimling, A (2015). ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 129(1):133-146.

Wiestler, B; Capper, D; Hovestadt, V; Sill, M; Jones, D T W; Hartmann, C; Felsberg, J; Platten, M; Feiden, W; Keyvani, K; Pfister, S M; Wiestler, O D; Meyermann, R; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M; Wick, W (2014). Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 16(12):1630-1638.

Wiestler, B; Capper, D; Sill, M; Jones, D T W; Hovestadt, V; Sturm, D; Koelsche, C; Bertoni, A; Schweizer, L; Korshunov, A; Weiß, E K; Schliesser, M G; Radbruch, A; Herold-Mende, C; Roth, P; Unterberg, A; Hartmann, C; Pietsch, T; Reifenberger, G; Lichter, P; Radlwimmer, B; Platten, M; Pfister, S M; von Deimling, A; Weller, M; Wick, W (2014). Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 128(4):561-571.

Wick, W; Weller, M; van den Bent, M; Sanson, M; Weiler, M; von Deimling, A; Plass, C; Hegi, M; Platten, M; Reifenberger, G (2014). MGMT testing-the challenges for biomarker-based glioma treatment. Nature Reviews. Neurology, 10(7):372-85.

Weller, M; Kaulich, K; Hentschel, B; Felsberg, J; Gramatzki, D; Pietsch, T; Simon, M; Westphal, M; Schackert, G; Tonn, J C; von Deimling, A; Davis, T; Weiss, W A; Loeffler, M; Reifenberger, G (2014). Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 134(10):2437-2447.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Weiler, M; Blaes, J; Pusch, S; Sahm, F; Czabanka, M; Luger, S; Bunse, L; Solecki, G; Eichwald, V; Jugold, M; Hodecker, S; Osswald, M; Meisner, C; Hielscher, T; Rübmann, P; Pfenning, P N; Ronellenfitsch, M; Kempf, T; Schnölzer, M; Abdollahi, A; Lang, F; Bendszus, M; von Deimling, A; Winkler, F; Weller, M; Vajkoczy, P; Platten, M; Wick, W (2014). mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 111(1):409-414.

Wiestler, B; Capper, D; Holland-Letz, T; Korshunov, A; von Deimling, A; Pfister, S M; Platten, M; Weller, M; Wick, W (2013). ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica:Epubahead of print.

Koelsche, C; Sahm, F; Capper, D; Reuss, D; Sturm, D; Jones, D T W; Kool, M; Northcott, P A; Wiestler, B; Böhmer, K; Meyer, J; Mawrin, C; Hartmann, C; Mittelbronn, M; Platten, M; Brokinkel, B; Seiz, M; Herold-Mende, C; Unterberg, A; Schittenhelm, J; Weller, M; Pfister, S; Wick, W; Korshunov, A; von Deimling, A (2013). Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 126(6):907-915.

Hartmann, C; Hentschel, B; Simon, M; Westphal, M; Schackert, G; Tonn, J C; Loeffler, M; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M (2013). Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clinical Cancer Research, 19(18):5146-5157.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Weiler, M; Pfenning, P N; Thiepold, A L; Blaes, J; Jestaedt, L; Gronych, J; Dittmann, L M; Berger, B; Jugold, M; Kosch, M; Combs, S E; von Deimling, A; Weller, M; Bendszus, M; Platten, M; Wick, W (2013). Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene, 32(9):1099-1109.

Capper, D; Simon, M; Langhans, C D; Okun, J G; Tonn, J C; Weller, M; von Deimling, A; Hartmann, C (2012). 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 131(3):766-768.

Hegi, M E; Janzer, R C; Lambiv, W L; Gorlia, T; Kouwenhoven, M C M; Hartmann, C; von Deimling, A; Martinet, D; Besuchet Schmutz, N; Diserens, A C; Hamou, M F; Bady, P; Weller, M; van den Bent, M J; Mason, W P; Mirimanoff, R O; Stupp, R; Mokhtari, K; Wesseling, P (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123(6):841-852.

Christians, A; Hartmann, C; Benner, A; Meyer, J; von Deimling, A; Weller, M; Wick, W; Weiler, M (2012). Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE, 7(3):e33449.

Opitz, C A; Litzenburger, U M; Sahm, F; Ott, M; Tritschler, I; Trump, S; Schumacher, T; Jestaedt, L; Schrenk, D; Weller, M; Jugold, M; Guillemin, G J; Miller, C L; Lutz, C; Radlwimmer, B; Lehmann, I; von Deimling, A; Wick, W; Platten, M (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478(7368):197-203.

Weller, M; Wick, W; von Deimling, A (2011). Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia, 59(8):1200-1204.

Hartmann, C; Hentschel, B; Tatagiba, M; Schramm, J; Schnell, O; Seidel, C; Stein, R; Reifenberger, G; Pietsch, T; von Deimling, A; Loeffler, M; Weller, M (2011). Molecular markers in low-grade gliomas: predictive or prognostic? Clinical Cancer Research, 17(13):4588-4599.

Weiler, M; Hartmann, C; Wiewrodt, D; Herrlinger, U; Gorlia, T; Bähr, O; Meyermann, R; Bamberg, M; Tatagiba, M; von Deimling, A; Weller, M; Wick, W (2010). Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. International Journal of Radiation Oncology, Biology and Physics, 77(3):670-676.

Berger, B; Capper, D; Lemke, D; Pfenning, P N; Platten, M; Weller, M; von Deimling, A; Wick, W; Weiler, M (2010). Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 12(9):894-907.

Hartmann, C; Hentschel, B; Wick, W; Capper, D; Felsberg, J; Simon, M; Westphal, M; Schackert, G; Meyermann, R; Pietsch, T; Reifenberger, G; Weller, M; Loeffler, M; von Deimling, A (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 120(6):707-718.

Weller, M; Felsberg, J; Hartmann, C; Berger, H; Steinbach, J P; Schramm, J; Westphal, M; Schackert, G; Simon, M; Tonn, J C; Heese, O; Krex, D; Nikkhah, G; Pietsch, T; Wiestler, O; Reifenberger, G; von Deimling, A; Loeffler, M (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology, 27(34):5743-5750.

Wick, W; Hartmann, C; Engel, C; Stoffels, M; Felsberg, J; Stockhammer, F; Sabel, M C; Koeppen, S; Ketter, R; Meyermann, R; Rapp, M; Meisner, C; Kortmann, R D; Pietsch, T; Wiestler, O D; Ernemann, U; Bamberg, M; Reifenberger, G; von Deimling, A; Weller, M (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 27(32):5874-5880.

Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J; Wolter, M; Mawrin, C; Wick, W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken, J W M; Wesseling, P; Reifenberger, G; von Deimling, A (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 118(4):469-474.

Kiening, K L; van Landeghem, F K H; Schreiber, S; Thomale, U W; von Deimling, A; Unterberg, A W; Stover, J F (2002). Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neuroscience Letters, 324(2):105-108.

van Landeghem, F K; Stover, J F; Bechmann, I; Brück, W; Unterberg, A; Bührer, C; von Deimling, A (2001). Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia, 35(3):167-179.

This list was generated on Mon Dec 11 16:04:20 2017 CET.